Improving health-related quality of life is a major therapeutic goal following TAVI in patients with aortic stenosis. In a prespecified analysis published in the Journal of the American College of Cardiology (JACC), the DapaTAVI (Dapagliflozin After Transcatheter Aortic Valve Implantation) trial evaluated whether dapagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, could further enhance postprocedural health status.

The randomized controlled trial included 964 patients who received either dapagliflozin or standard care. Health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 3 and 12 months. Both groups demonstrated marked improvement in KCCQ scores, reflecting substantial recovery in symptoms and functional capacity.

However, dapagliflozin did not provide additional benefit at either time point (3 months: odds ratio [OR] 0.96; 95% confidence interval [CI] 0.72–1.26; 12 months: OR 1.03; 95% CI 0.83–1.27). At one year, approximately 44% of patients in both groups achieved clinically meaningful improvement.

These findings indicate that while TAVI alone significantly enhances patient well-being, dapagliflozin does not offer additional benefit in health-related quality of life or heart failure outcomes following the procedure.